Aussie MS breakthrough stops disease progression

Queensland researcher Professor Michael Pender and collaborators from the QIMR Berghofer Medical Research Institute have published a case study of a new treatment that involved using a vaccine for Epstein–Barr virus (EBV) along with immune cells from blood to halt disease progression in the man with secondary progressive MS.

The patient, Gary Allen, said he began noticing a positive response almost immediately with the beneficial effects sustained 12 months on. He has experienced a significant reduction in fatigue and spasms, an improvement in cognitive skills and